7462-84-2

Usage

Uses

Used in Pharmaceutical Industry:
1-methylpiperidine-4-carbonyl chloride hydrochloride is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy and safety of existing medications.
Used in Organic Synthesis:
1-methylpiperidine-4-carbonyl chloride hydrochloride is used as a reagent in organic synthesis for the preparation of a wide range of compounds, facilitating the creation of new chemical entities and enhancing the scope of chemical research.
Used in Research and Development:
1-methylpiperidine-4-carbonyl chloride hydrochloride is utilized in research and development within the pharmaceutical industry, enabling scientists to explore its potential applications and optimize its use in drug discovery and synthesis processes.

InChI:InChI=1/C7H12ClNO/c1-9-4-2-6(3-5-9)7(8)10/h6H,2-5H2,1H3

Upstream product

• 68947-43-3 1-methylpiperidine-4-carboxylic acid 

Downstream Products

• 1401732-23-7 C₂₆H₂₉N₇O₂ 
• 1253585-49-7 N-{5-[2,4-dihydroxy-6-(4-nitrophenoxy)phenyl]isoxazol-3-yl}-1-methylpiperidine-4-carboxamide 
• 857402-57-4 C₇H₁₃NO₂*C₃₁H₄₅N₃O₈*ClH 

Relevant academic research and scientific papers

SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3,4-B] PYRIDINE AND PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b] pyridine, 5-(pyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine and pyrazolo [3,4-b] pyridine derivatives according to formula I, II and VII, and methods for making same, which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson?s disease, Alzheimer?s disease, Down?s Syndrome, Huntington?s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases. Also disclosed are pharmaceutical compositions including the compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated there with using compounds and pharmaceutical compositions including the compounds.

PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS

The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.